Recent advances in topical wound care

Sujata Sarabahi
Department of Burns and Plastic Surgery, VMMC and Safdarjung Hospital, New Delhi, India

Address for correspondence: Dr. Sujata Sarabahi, B-18, 1st Floor, Kailash Colony, New Delhi, India. E-mail: drssarabahi@gmail.com

ABSTRACT

There are a wide variety of dressing techniques and materials available for management of both acute wounds and chronic non-healing wounds. The primary objective in both the cases is to achieve a healed closed wound. However, in a chronic wound the dressing may be required for preparing the wound bed for further operative procedures such as skin grafting. An ideal dressing material should not only accelerate wound healing but also reduce loss of protein, electrolytes and fluid from the wound, and help to minimize pain and infection. The present dictum is to promote the concept of moist wound healing. This is in sharp contrast to the earlier practice of exposure method of wound management wherein the wound was allowed to dry. It can be quite a challenge for any physician to choose an appropriate dressing material when faced with a wound. Since wound care is undergoing a constant change and new products are being introduced into the market frequently, one needs to keep abreast of their effect on wound healing. This article emphasizes on the importance of assessment of the wound bed, the amount of drainage, depth of damage, presence of infection and location of wound. These characteristics will help any clinician decide on which product to use and where, in order to get optimal wound healing. However, there are no ‘magical dressings’. Dressings are one important aspect that promotes wound healing apart from treating the underlying cause and other supportive measures like nutrition and systemic antibiotics need to be given equal attention.

KEYWORDS
Moist healing, topical wound care, wet dressings

INTRODUCTION

The practice of wound care has improved tremendously and evolved over the years. The Greek physician Galen (120-201 A.D) had noted empirically that wounds heal optimally in a moist environment. However, for almost 2000 years, therapeutic efforts had focussed on drying the wound site with absorptive gauzes serving as mainstay for wound management. They even facilitated debridement, if used as a wet to dry dressing. The value of these gauze dressings is now questionable because of the pain and damage that they cause to the neo-epithelium during removal.

In 1962, Winter noticed that occluded wounds required less time for epithelialization compared to wounds left open to air, which was supported by Cho and Lo, 1998.[2] A closed dressing exposes the wound continuously to proteinases, chemotactic, complement & growth factors in the surrounding fluid, which may be otherwise lost in case the wound is left exposed.[3] Even the electrical gradient required for stimulation of fibroblasts and epithelial cell migration is maintained and further trauma to the wound is avoided by this physical barrier.
In late 20th century, more clinical data was published in support of this and manufacturers began producing occlusive wound dressings, which were designed to preserve and protect a moist environment in the wound. Newer occlusive dressings speed up re-epithelialization, stimulate collagen synthesis, create a hypoxic environment at the wound bed to promote angiogenesis & decrease pH at wound surface, creating an environment inhospitable to bacterial growth, which decreases the rate of wound infection. They have an edge over gauze dressings in terms of patient comfort, convenience and compliance as well as better cosmetic results because of reduced scarring.

The idea of developing modern dressings is to manipulate the wound environment in purposeful ways. The enormous array of products available in the market today makes selection of the most appropriate dressing for any wound a very difficult task.

However, the basic principles of wound management should not be ignored and these therapeutic modalities should not be used as a panacea to wounds, which can lead to disasters.

**Topical wound care products**

Dressings can be classified into passive and interactive dressings. Passive dressings are simple products like gauze which have no direct effect on the wound except protecting it. Most modern dressing products are interactive dressings as they interact with the wound bed to provide optimum environment at the wound dressing interface. The basic requirements of an appropriate wound dressing was given by Scales in 1956 much before the principles of moist wound healing were recognized by Winter[1][Table 1].

The technology has advanced with the realization that moist environment is beneficial for healing so it is now possible to design dressing products which have characteristics of an ideal dressing.[1,10] The moisture vapour transmission rate (MVTR) measures the moisture retentive property of a dressing. A dressing is moisture retentive if its MVTR is less than 840g/m2/24 hrs.[11,12] The MVTR of hydrocolloids is less than 300g/m2/24 hrs, in contrast to gauze whose MVTR is 1200g/m2/24 hrs. MVTR is a useful tool for choosing dressing according to the wound type. Currently many dressings are commercially available, however, none can be labelled as ideal for all wounds [Table 2].

**Topical antiseptics and antimicrobials**

Although it is established through *in vitro* studies that many of the antiseptic agents have cytotoxic properties,[13] but if used correctly they can be very effective. Current literature reveals that antiseptics can be used selectively as first line of treatment of critically colonized or infected wounds, eradication of MRSA from contaminated wounds, to stimulate previously unresponsive chronic wounds and against biofilms.[14-15, 16] The antiseptics used very commonly are hydrogen peroxide, iodine-based preparations and Eusol.

Antimicrobials are available in various forms for topical use and the most commonly used ones are Bacitracin A, Neomycin, Fucidin, Mupirocin, Retapamulin.[Table 3] These serve as moist dressings. However, because of its extensive use the incidence of resistance to mupirocin is also increasing, to the rate of 11-65%.[17]

**Silver impregnated dressings**

Silver is well known as an antiseptic agent (silver nitrate and silver sulphadiazine) for ages. However, the delivery system in the form of a salt has been a limiting factor for its successful and widespread biological use. Recently, silver has been incorporated into different wound dressing products like gauzes, hydrocolloids, alginates,
foams, creams and gels but each of them differ in the way in which silver ions are released. There have been advances in the delivery technology with discovery of the nanocrystalline structure of silver. Silver nitrate and silver sulphadiazine release silver at concentration of 3200 ppm. Most pathogenic organisms are killed invitro at concentration of 10-40 ppm. The development of nanochemistry has produced micro fine particles which increase silver’s solubility and releases silver ions in concentration of 70-100 ppm. Nanocrystalline silver system kills all microbes found in the wound including fungi, MRSA and vancomycin-resistant enterococcus (VRE).[18]

Silver absorbed by epidermal cells induces production of metallothione which in turn increases uptake of zinc and copper, which increases RNA and DNA synthesis. This then promotes cell proliferation and tissue repair.[20] In any case of non-healing chronic wound there is an excess of matrix metalloproteinases (MMP), which increases the inflammation and inflammatory cell exudates and degrade the growth factors. Nanocrystalline silver decreases the MMP activity both invitro and invivo because of its inhibitory effect on zinc activity, which is required for MMPs, as also its inhibitory effect on release of proinflammatory cytokines and tumour necrosis factor–alpha.

The Acticoat dressing is a three layered dressing consisting of an absorbent rayon/polyester core laminated between upper and lower layer of silver-coated high density polyethylene mesh. The silver concentration on the wound surface is 20-30 times greater than the concentration required to kill microbes. These nanocrystalline dressings can be left in place for up to 5-7 days, which avoids trauma to the new epithelial growth.

**Foam**

Foam dressings are highly absorbent polyurethane dressings, available as pads, sheets and cavity dressings. They create a moist environment and provide thermal insulation to the wound. They are nonadherent, easy to apply and remove and are meant for highly exuding wounds. They can be layered in combination with other materials with overlying compression bandages. Their fluid absorption capacity varies with foam thickness; therefore, their MVTR ranges between 800-5000g/m²/24 hrs. They may be used for their cushioning effect but they are not a substitute for pressure relieving devices. In terms of ulcer healing they have been found comparable to hydrocolloids according to some studies.[21] Foams may produce excessive malodorous drainage necessitating frequent dressing change.[22]

**Alginates**

Alginates are composed of soft, non-woven fibres, which contain calcium and sodium salts of alginic acid. When placed over a moist wound, an ion exchange reaction occurs between calcium in the alginate and sodium in the wound fluid producing soluble calcium–sodium alginate – a gelatinous mass, which helps in maintaining moist environment and facilitates autolytic debridement.[23] They conform to the shape of the wound and should be cut according to the shape of wound because if larger they can cause periwound maceration because of their tendency to absorb fluid across entire surface (lateral wicking).[24] They are used as fillers for undermined and tunnelled wounds. They are highly absorbent (absorbs 20 times its weight). They may leave fibrous debris in the wound, which is claimed to get biodegraded yet there have been reports of them causing long-term foreign body type reactions.[25] Some studies have suggested that alginates are inhibitory to keratinocytes,[26] whereas others have reported that alginates accelerate wound healing when compared to control dressing.[27]

**Hydrocolloids**

Hydrocolloids are composed of gelatine, pectin and or carboxymethylcellulose, and serve as occlusive or semi-occlusive dressings. They are impermeable to water, bacteria and other contaminants but permeable to water vapour. They absorb wound exudates to form a hydrophilic gel. Most important advantage is their long wear time, which decreases the cost, inconvenience and local trauma associated with dressing changes.

They are not indicated for arterial/neuropathic ulcers, infected or heavily exuding wounds because of risk of periwound maceration. Another down side of the treatment is their tendency to produce malodorous exudates, which can be mistaken for infection.[28,29]

**Hydrofibres**

Hydrofibres are sterile sodium carboxymethyl cellulose fibres. They conform to the wound surface, are highly absorbent and interact with wound exudates to form a gel. They thus maintain a moist environment and allow autolytic debridement. They are indicated for pressure ulcers, lower limb ulcers and surgical wounds. Eg: Aquacel hydro fibre (Convatec).
Hydrogels
Hydrogels are polymers, glycerine or water-based gels, impregnated gauzes or sheet dressings. Their high water content does not allow them to absorb large amount of exudates so they cannot be used on heavy exuding wounds. They have a gentle yet effective debriding and desloughing action by rehydrating necrotic tissue and removing it without damaging healthy tissue and absorbing slough and exudates. They rehydrate the wound bed, reduce pain because of their cooling effect, are non-adhesive, fill dead spaces, are easy to apply and remove.[30-32] They are best suited for dry wounds or those with minimal exudates. But they require a secondary dressing.

Transparent films
Transparent films are adhesive, semi permeable, polyurethane membrane dressings which vary in size and configuration. They are waterproof but permit water vapour and atmospheric gases to cross but are impermeable to contaminants and bacteria. Since these films are transparent, wounds can be inspected without removing the dressing. They are flexible and easily conformable making them ideal for wounds on joints and hands. They are used on partial thickness wounds with minimal exudates, pressure ulcers, grafts and aim to secure other wound dressings.

Debridement
The clinician has the choice of different methods of debridement and the latest techniques are as follows:

Enzymatic debridement
Collagenase and papain, which are available as ointments have been used for over a quarter of a century for this purpose. They aid in digesting necrotic tissue without damaging healthy tissue. Collagenase, is a proteolytic enzyme which specifically attacks and breaks down native collagen and is gentle on viable cells. It is therefore useful in maintenance phase of wound debridement, i.e., gradual breakdown of tissue.[33]

However, papain, obtained from papaya fruit breaks down cysteine residues in proteins but is nonselective and is associated with intense inflammatory response and breakdown of viable portions of wound bed, thereby associated with considerable pain.[33] Urea is combined to increase its proteolytic action. E.g.: Debridace (Virchow Healthcare).

High pressure water irrigation
Hydrocision or pressurized irrigation (Versa jet, Smith & Nephew) has now entered the foray of tools in surgical debridement and cleaning of the wound with either high or low pressure, razor thin stream of water, saline or antibiotic solution and is serving as a better alternative compared to the above methods.

High pressure irrigation is effective in removing bacteria, particulate matter and necrotic debris from the wounds, thus lowering the rate of infection compared to low pressure irrigation.[36,34] The only concern is that there is a risk of bacteria being driven into soft tissue by the high pressure. It is particularly useful in concavities of pressure sores and joint spaces and in tight spaces. It is indicated for use in necrotic wounds and deep burns also.[35] Since it preserves the viable dermal tissue it allows rapid wound healing with better cosmetic outcome.

Biodebridement by medicated larvae (myiasis or maggot therapy)
The practice of using maggots for wound debridement has been around for centuries. Recently, there is a revival of their use because of the ability to breed sterile flies commercially.[36] There has been recent interest in the use of larvae of green Bottle fly (Luciliaserricata), which is used in large ulcers having large amount of necrotic material. Their secretions contain proteolytic enzymes, which digests only necrotic debris and slough and also enzymes which are bactericidal effective against MRSA and b-haemolytic streptococcus but do not disturb normal host tissue.[37] The selective debridement can be achieved within two days. Larvae can be left in place for 3 days but may need to be changed sooner if there is increase in pain because of change in wound pH. The main drawbacks of this therapy are local discomfort, itching, unaesthetic appearance to the patient along with cost of the therapy and short half life of maggots. But despite them it is beginning to establish a recognized role in wound therapy.[38]

Negative pressure wound therapy
Negative pressure wound therapy (NPWT) or vacuum-assisted closure (VAC) has played a major role as a bridge to reconstruction. It is a significant, clinically proven advancement in wound care that promotes active wound healing at the cellular level through negative pressure. Pressure used is negative pressure or sub atmospheric pressure (100-125 mm Hg) in a continuous or intermittent manner.[39-41] The intermittent negative pressure is delivered at wound site through a porous dressing, which applies mechanical forces known as macro strain (physical response) and micro strain (biological response) and
Growth factors

Growth factors are naturally occurring proteins in the body which control many key cellular activities during normal tissue repair process. There is evidence that macromolecules present in the wound fluid and bed trap growth factors within fibrin cuffs in the surrounding capillaries or bind them to the extracellular matrix.[42-44] As a result, there is deficiency of growth factors in the wound bed and the cells are arrested in the cell cycle thereby affecting the healing process in chronic wounds. Growth factors can be obtained either autogenously by utilizing body’s platelets or macrophages or can be produced outside the body chemically or biochemically (recombinant). Studies have suggested that exogenous application of these factors to wound surface may benefit healing process.[8]

Multiple studies have shown beneficial effect of factors like Recombinant human Platelet derived growth factor (rhPDGF), Fibroblast growth factor, granulocyte – macrophage colony stimulating factors and Epidermal growth factor (EGF) either alone or in combination accelerating healing in chronic wounds.[45-48] PDGF and EGF are the only topical growth factor approved by US FDA for treatment of chronic wounds.[49] PDGF promotes chemotactic recruitment and proliferation of cells involved in wound repair. EGF also regulates cell proliferation, migration and differentiation through binding to receptor kinases on target cells and induce angiogenesis.

Skin substitutes

In recent years, a wide array of biologically active material and skin substitutes have been developed which address the various challenges encountered during wound healing. Some of them have been used as dressings, which protect wound from fluid loss and infection and others are being used as wound implants, which help replace extracellular matrix molecules or deliver various growth factors to prepare bed for permanent skin coverage.

Collagen

Collagen produced by fibroblasts is the most important constituent of connective tissue. Out of the many subtypes, type I is mostly seen in healing tissues. Chronic wounds are now treated with topical collagen products that improve wound healing by laying down a matrix which favours deposition of new tissue and attracts cells necessary for healing. The collagen is thought to be chemotactic for fibroblasts and macrophages and also provide a temporary scaffold to allow in growth of tissue.[50] They are usually of human, porcine or bovine origin and are available as particle or sheet form. They absorb wound exudates to form a soft biodegradable gel over the wound surface, which maintains wound moisture.[51]

Topical insulin

The idea of using insulin topically has been around for decades dating back to 1960s (greenway).[52] Since then there have been many experiments on animals as well as humans but the usefulness of insulin in wound healing still remains speculative and safety issues still have to be addressed.[53] Topical insulin in combination with zinc in animal studies has shown to heal wounds faster.[54] It regulates wound inflammatory response by stimulating proliferation and migration of macrophages and keratinocytes in adjacent tissues.[55,56] However, no suitable method for routine administration of insulin has been reported.

Topical antioxidants

Effect of topical vitamin E, which is a major lipid soluble antioxidant, on wound healing and scar formation remains inconclusive as some reports claim it is valuable for speeding wound healing and improving outcome of scars and other studies have shown that it has no effect.[57-59]

Oxygen is a prerequisite for successful wound healing because of increase demand during reparative processes like cell proliferation, angiogenesis, collagen synthesis and bacterial defence. Many studies have shown wound healing impaired under hypoxia and improvement with systemic and topical oxygen therapy yet its efficacy is inconsistent.[60,61]

Future of wound care

Inspite of all the above mentioned options there are many wounds resistant to treatment and a variety of new techniques are being researched. These include tissue engineering techniques like stem cells and gene therapy for achieving wound closure.[62,63] Stem cells have the ability to migrate to the site of injury or inflammation, participate in regeneration of damaged tissue, stimulate proliferation and differentiation of resident progenitor cells, secreting growth factors, remodelling matrix, increasing angiogenesis, inhibiting scar formation and improving tensile strength of the wound.[64-67] ADSC alone or with platelet rich plasma is a promising tool in chronic wound healing but the delivery techniques
### Table 3: Summary of newer topical wound care products

| Product | Indication and action | Advantages | Disadvantages | Use | Examples |
|---------|-----------------------|------------|---------------|-----|----------|
| **Antimicrobials** | | | | | |
| Mupirocin | Wounds infected with gram positive organisms Prevents bacterial protein and cell wall synthesis | Very effective against staphylococcus especially mrsa Do not damage healthy tissue | Costly | Can be applied daily | T-bact (glaxo), bactroban, mupibact |
| Retapamulin | Effective against staphylococcus aureus and pyogens Inhibit bacterial protein synthesis | Effective against mupirocin and fucidin resistant staphylococcus. | Costly | | Retral (Ajanta pharma) |
| **Silver impregnated dressings** | Deep burns Skin sloughing disorders (toxic epidermal necrolysis and steven johnson syndrome), donor sites and meshed skin grafts | Effective for wounds infected both with gram negative and gram positive organisms esp mrsa and vre and fungi also | Argyria costly | Change every 5-7 Days | Acticoat (Smith and Nephew), silvel (Datta phatra), Biatainag (coloplast) actisorb (johnson and johnson) Aquasel ag (Convatec) |
| **Foams** | Pressure ulcers And lower limb ulcers with min to mod exudates | Absorbent Occlusive Thermal insulation | Opaque Malodorous discharge | Change every 3 Days | Alleyn (smith and Nephew), lyofoam (convatec), 3 m foam dressing (3m health care), biatain foam dressing (Coloplast) |
| **Films** | Partial thickness Wounds with minimal exudates, pressure ulcers, grafts | Transparent Occlusive moisture retentive protection from contamination Easy to inspect wounds | No absorption Fluid trapping skin stripping not for infected wounds | Leave on till 7 Days or when fluid leaks or secretions collect underneath | Tegaderm (3 m Healthcare), biocclusive (Johnson and Johnson), Opsite (smith and nephew), dermasite (dermasciences), comflee film (coloplast). Intrasite gel (Smith and nephew), Solosite (smith & nephew) , restore (Hollister) |
| **Hydrogels** | Dry wounds Painful wounds mainly pressure sores, lower limb ulcers, skin tears and surgical wounds. | Moisture retentive Nontraumatic removal | May over hydrate | Change in 1-3 Days | |
| **Hydrocolloids** | Wounds with min To mod exudates like pressure ulcers and venous stasis ulcers s | Absorbent Occlusive protection from contamination | Opaque Fluid trapping malodorous discharge | Left on till 7 Days | Duoderm (Convatec), comfeel (coloplast), 3 m tegasorb (3m health care), restore (hollister), Nuderm (Johnson and Johnson). |
| **Alginates** | Pressure sores, Diabetic ulcers, Infected wounds, Lower extremity ulcers with moderate to heavy exudates Mild hemostasis | Highly absorbent Hemostatic Non-toxic, non allergenic | Fibrous debris | Left on till Soaked with exudate | Kaltostat (Convatec), Algiderm (bard), kalginate (de royal). |
| **Enzymatic Debridement** | For necrotic Sloughy wounds | Digest necrotic matter Without harming normal tissue | Papain is Nonselective and may be painful No absorbing action so need a secondary dressing | Minimum daily use | Collagenase Santyl (healthport), Accuzyme (healthport), salutyl (elder pharma). Debridace (virchow healthcare) |

(Table 3 continue...)
Sarabahi: Topical wound care products

and complete effect needs to be studied and refined.\(^6\)

Recently, stem cell-based skin engineering along with gene recombination represents an alternative tool for regenerative strategy for wound therapy.\(^6,7\)

Current drug delivery strategies cannot control loss of drug activity due to physical inhibition and biological degradation. So to optimize the delivery of factors for maximum efficacy a molecular genetic approach is being researched in which genetically modified cells synthesize and deliver the desired growth factor in a time regulated and locally restricted manner to the wound site to promote wound healing. Their action may be further strengthened by implanting them in a biomaterial scaffold which promotes cell adhesion, proliferation, migration and differentiation. Stem cells might emerge as an exciting target for gene transfer in tissue repair.\(^7\)

If stem cells could be instructed to differentiate into one particular lineage and functionally integrate into injured tissue environment, they can replace cells that have been lost.

**CONCLUSION**

Wound management has made rapid advances over the last 25 years and with increase in the understanding of the biology of chronic non-healing wounds, this advancement is likely to continue. In the rush to utilize the newer wound treatments, clinicians should not neglect the basics of good wound care if they want to derive maximum benefits from these evolving technologies and therapies. Clear guidelines focussing on the principles of effective wound bed preparation have been laid and they have to be followed to ensure effective patient outcome with the use of newer wound care products. [Table 3]

Dressing selection depends on the practitioner’s skilled assessment of the wound and his knowledge of how to provide this optimum wound healing environment through the use of modern interactive dressings.

The plethora of wound care products in the market has resulted in practitioner’s using a combination of products, which may make the treatment very expensive. However, even if a certain dressing is expensive but promotes wound healing rapidly leading to the desired clinical results, it can be judged to be cost effective.

**REFERENCES**

1. Winter GD.Formation of scab and rate of epithelialization of superficial wounds in the skin of the young domestic pig. Nature 1962;193:293-4.
2. Cho CY, Lo JS.Excision and repair: Dressing the part. DermatolClin1998;16:25-47.
3. Moon CH, Crabtree TG.New wound dressing techniques to accelerate healing. Curr Treat Options Infect Dis 2003;5:251-60.
4. Varghese MC, Balin AK, Carter DM, Caldwell D. Local environment of chronic wounds under synthetic dressings. Arch Dermatol 1986;12:52-7.
5. Alvarez OM, Mertz PM, Eaglenstein WH.The effect of occlusive dressings on collagen synthesis and re-epithelialization in superficial wounds. J Surg Res 1983;35:142-8.

Indian Journal of Plastic Surgery May-August 2012 Vol 45 Issue 2
6. Rubio PA. Use of semiocclusive, transparent film dressings for surgical wound protection: An experience in 3637 cases. Int Surg 1991;76:253-4.

7. Jones AM, San Miguel L. Are modern wound dressings a clinical and cost effective alternative to the use of gauze? J Wound Care 2006;15:65-9.

8. Robson MC, Smith PD. Topical use of growth factors to enhance healing. In: Falanga V, editor. Cutaneous wound healing. London: Martin Dunitz, Ltd; 2001. p. 379-98.

9. Scales JT. Development and evaluation of a porous surgical dressing. Br Med J 1956;2:962-81.

10. Himman CD, Maibach H. Effect of air exposure and occlusion on experimental human skin wounds. Nature 1963; 200:377-8.

11. Field KJ, Kerstein MD. Overview of wound healing in a moist environment. Am J Surg 1994;167:2S-6S.

12. Bolton LL, Monte K, Pirone LA. Moisture and healing: Beyond the jargon. Ostomy Wound Manage 2000;46(1A Suppl):51S-62S; quiz 63S-64S.

13. Lineaweaver W, Howard R, Soucy D, Mc Morris S, Freeman J, Crain C, et al. Topical antimicrobial toxicity. Arch Surg 1985;120:267-70.

14. White RJ, Cutting K. Kingsley T. Topical antimicrobials in the control of wound bioburden. Ostomy Wound Manage 2006;52:26-58.

15. Lawrence JC. The use of iodine as an antiseptic agent. J Wound Care 1998;7:421-5.

16. Schults GS, Sibbald GR, Falanga V, Ayello E, Dowsett C, Harding K, et al. Wound bed preparation: A systematic approach to wound management. Wound Repair Regen 2003;11:1-28.

17. Lio PA, Raye ET. Topical antibacterial agents. Infect Dis Clin North Am 2009;23:945-63.

18. Lansdown AB. Silver in health care: Antimicrobial effects and safety in use. Curr Probl Dermatol 2006;33:17-34.

19. Lansdown AB. Metallothioneins: Potential therapeutic aids for wound healing in the skin. Wound Repair Regen 2002;10:130-2.

20. Demling RH, Leslie De Santi M. The rate of re-epithelialization across meshed skin grafts is increased with exposure to silver. Burns 2002;28:264-6.

21. Bradley M, Cullum N, Nelson EA, Petticrew M, Sheldon T, Torgerson D. Systematic reviews of wound care management (2) dressings and topical agents used in healing of chronic wounds. Health Technol Assess 1999;3:1-35.

22. Rubin JR, Alexander J, Plecha EJ, Arman C. Unna's boot vs. dressings and topical agents used in healing of chronic wounds. In: Falanga V, editor. Cutaneous wound healing. London: Martin Dunitz, Ltd; 2001. p. 379-98.

23. Bolten LL, Monte K, Pirone LA. Moisture and healing: Beyond the jargon. Ostomy Wound Manage 2000;46(1A Suppl):51S-62S; quiz 63S-64S.

24. Minor MJ, Arbegast RA. Br Med J 1956;2:962-81.

25. Field KJ, Kerstein MD. Overview of wound healing in a moist environment. Am J Surg 1994;167:2S-6S.

26. Brem H, Balleux J, Bloom T, Kerstein MD, Hollander L. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg 2000;135:627-34.

27. Margolis DJ, Bartus C, Hoffstad O, Malay S, Berlin JA. Effectiveness of recombinant human PDGF for treatment of diabetic neuropathic foot ulcers. Wound Repair Regen 2005;13:531-6.

28. Mian M, Beghe F, Mian E. Collagen as a pharmacological and basic foundation. Ann Plast Surg 1997;38:553-62.

29. Bottin JM, Attinzer CE, Mesabahi AN, Hess C, Grawk S. Mechanisms and clinical application of VAC device: A review. Am J Clin Dermatol 2005;6:185-94.

30. Higley HR, Ksander GA, Gerhardt CO, Falanga V, Extravasation of macromolecules and possible trapping of transforming growth factors—beta in venous ulcerations. Br J Dermatol 1995;132:79-85.

31. Trengove NJ, Stacey MC, MacAuley S. Analysis of acute and chronic wound environment: The role of proteases and their inhibitors. Wound Repair Regen 1999;7:142-4.

32. Trengrove NJ, Bielefeldt-Oathom H, Stacey MC. Miogenic activity and cytokine levels in nonhealing and healing chronic leg ulcers. Wound Repair Regen 2000;8:13-25.

33. Greenhalgh DG. The role of growth factors in wound healing. J Trauma 1996;41:159-67.

34. Hardinge KG, Morris HL, Patri GK. Science, medicine and the future: Healing chronic wound s. BMJ 2002;324:160-3.

35. Robson MC, Mustoe TA, Hunt TK. The future of recombinant growth factors in wound healing. Am J Surg 1998;176 (suppl 2A):805-82S.

36. Brem H, Balleux J, Bloom T, Kerstein MD, Hollander L. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg 2000;135:627-34.

37. Margolis DJ, Bartus C, Hoffstad O, Malay S, Berlin JA. Effectiveness of recombinant human PDGF for treatment of diabetic neuropathic foot ulcers. Wound Repair Regen 2005;13:531-6.

38. Mian M, Beghe F, Mian E. Collagen as a pharmacological approach in wound healing. Int J Tissue React 1992;14;S1-9.

39. Hess CT. Wound care. 5th ed. Baltimore MD: Lippincott Williams and Wilkins; 2005.

40. Brem H, Balleux J, Bloom T, Kerstein MD, Hollander L. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg 2000;135:627-34.

41. Wilson JM, Baines R, Babu ED, Kelley CJ. A role of topical insulin in the management of problematic surgical wounds. Ann R Coll Surg Engl 2008;90:160.
et al. Local insulin zinc injection accelerated skin closure donor site wound healing. J Surg Res 2007;142:90-6.
54. Greenway SE, Filler LE, Greenway FL. Topical insulin in wound healing: A randomized double-blind, placebo controlled trial. J Wound Care 1999;8:526-8.
55. Rezvani O, Shabbak E, Aslam A, Bidar R, Jafari M, Safanezhad S. A randomized double blind placebo controlled trial to determine the effects of topical insulin on wound healing. Ostomy Wound Manage 2009;55:22-28.
56. Chen X, Liu Y, Zhang X. Topical insulin application improves healing by regulating the wound inflammatory response. Wound Repair Regen 2010;20:425-34.
57. Baumann LS, Spencer J. The effects of topical vitamin E on the cosmetic appearance of scars. Dermatol Surg 1999;25:311-5.
58. Pinnel SR. Regarding d-alpha-Tocopherol. Dermatol Surg 1999;25:827.
59. Mackay D, Miller AL. Nutritional support for wound healing. Altern Med Rev 2003;8:359-77.
60. Schreml S, Szeimes RM, Prantl L, Karrer S, Landthaler M, Babillas P. Oxygen in acute and chronic wound healing. Br J Dermatol 2010;163:257-68.
61. Kallianien LK, Gordillo GM, Schlianger R, Sen CK. Topical oxygen as an adjunct to wound healing: A clinical case series. Pathophysiology 2003;9:81-7.
62. Hanson SE, Bentz ML, Hematti P. Mesenchymal stem cell therapy for nonhealing cutaneous wounds. Plast Reconstr Surg 2010;125:510-16.
63. Cha J, Falanga V. Stem cells in cutaneous wound healing. Clin Dermatol 2007;25:73-8.
64. Stoff A, Riviera AA, Banerjee NS, Moore ST, Numnum TM, Monteros A, et al. Promotion of incisional wound repair by human mesenchymal stem cell transplantation. Exp Dermatol 2009;18:362-9.
65. Yoshikama T, Mitsumo H, Nonaka I, Sen Y, Kawanishi K, Inada Y, et al. Wound therapy by marrow mesenchymal cell transplantation. Plast Reconstr Surg 2008;121:860-77.
66. Ko SH, Nauta A, Wong V, Glotzbach J, Gurtner GC, Longaker MT. The role of stem cells in cutaneous wound healing: What do we really know? Plast Reconstr Surg 2011;127(Suppl 1):10S-20S.
67. Cherubino M, Rubin JP, Mikjovic N, Kelmendi-Doko A, Marra KG. Adipose derived stem cells for wound healing applications. Ann Plast Surg 2011;66:210-15.
68. Lau K, Paus R, Tiede S, Day P, Bayat A. Exploring the role of stem cells in cutaneous wound healing. Exp Dermatol 2009;18:921-33.
69. Gauglitz GG, Jeschke MG. Combined gene and stem cell therapy for cutaneous wound healing. Mol Pharma 2011;8:1471-9.
70. Branski LK, Gauglitz GG, Herndon DN, Jeschke MG. A review of gene and stem cell therapy in cutaneous wound healing. Burns 2009;35:171-80.
71. Ianger R. Biomaterials in drug delivery and tissue engineering: onelaboratory's experience. Acc Chem Res 2000;33;94-101.
72. Korbling M, EstronZ. Adult stem cells for tissue repair – a new therapeutic concept? N Eng J Med 2003;349:570-82.
73. Eming SA, Kreig T, Davidson JM. Gene therapy and wound healing. Clin Dermatol 2007;25:79-92.

How to cite this article: Sarabahi S. Recent advances in topical wound care. Indian J Plast Surg 2012;45:379-87.

Source of Support: Nil, Conflict of Interest: None declared.